Developing a new treatment to prevent and treat inflammation-related colon cancer
Prevention and Therapy of Inflammation Associated Colorectal Cancer
This study is testing a new drug called MTDIA to see if it can help prevent and treat colon tumors caused by inflammation, using special mouse models that act like human colon cancer, with the hope of finding safer treatment options for people with this condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-11024638 on NIH RePORTER |
What this research studies
This research focuses on creating a new drug called MTDIA, which targets a specific enzyme involved in the metabolism of certain compounds in the body. The study aims to evaluate how effective MTDIA and its improved versions are in preventing and treating colon tumors linked to inflammation. Using innovative mouse models that mimic human colon cancer, researchers will assess the drug's ability to inhibit tumor growth without causing toxicity. The findings could lead to new therapeutic options for patients with inflammation-associated colorectal cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of inflammatory bowel disease or those at high risk for developing colorectal cancer.
Not a fit: Patients with non-inflammatory causes of colorectal cancer or those who do not have any form of bowel inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that effectively prevents and treats colorectal cancer associated with inflammation.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting metabolic pathways in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Augenlicht, Leonard H — Albert Einstein College of Medicine
- Study coordinator: Augenlicht, Leonard H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.